• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Esperion Therapeutics (ESPR)

Common Shares
Sell: $2.55|Buy: $2.56|Change: 0.06 (-2.30%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Address

3891 Ranchero Drive
Suite 150
Ann Arbor
MI
USA
48108

Telephone

+1 734 887-3903

Website

https://www.esperion.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Esperion Therapeutics Inc Fourth Quarter Earnings Conference Call for 20262027-03-10T08:00:00
Esperion Therapeutics Inc Fourth Quarter Earnings Results for 20262027-03-10T00:00:00
Esperion Therapeutics Inc Annual Report for 20262027-03-10T00:00:00
Esperion Therapeutics Inc Third Quarter Earnings Conference Call for 20262026-11-06T08:00:00
Esperion Therapeutics Inc Third Quarter Earnings Results for 20262026-11-06T00:00:00
Esperion Therapeutics Inc Second Quarter Earnings Conference Call for 20262026-08-05T08:00:00
Esperion Therapeutics Inc Second Quarter Earnings Results for 20262026-08-05T00:00:00
Esperion Therapeutics Inc Annual General Meeting for 20262026-05-29T08:00:00
Esperion Therapeutics Inc First Quarter Earnings Conference Call for 20262026-05-06T08:00:00
Esperion Therapeutics Inc First Quarter Earnings Results for 20262026-05-06T00:00:00
25th Annual Needham Virtual Healthcare Conference2026-04-13T09:30:00

Previous key dates

NameKey Date
25th Annual Needham Virtual Healthcare Conference2026-04-13T09:30:00
The Citizens Life Sciences Conference2026-03-11T08:25:00
Esperion Therapeutics Inc Fourth Quarter Earnings Conference Call for 20252026-03-10T08:00:00
Esperion Therapeutics Inc Fourth Quarter Earnings Result for 20252026-03-10T00:00:00
Esperion Therapeutics Inc Annual Report for 20252026-03-10T00:00:00
Esperion Therapeutics Strategic Update2026-03-03T08:00:00
J.P. Morgan's 44th Annual Healthcare Conference2026-01-14T17:15:00
Piper Sandler 37(th) Annual Healthcare Conference2025-12-03T15:30:00
Jefferies Global Healthcare Conference - London2025-11-18T15:00:00
Esperion Therapeutics Breaking the Statin Intolerance Barrier: Closing the Care Gap in Cardiovascular Health Conference Call 20252025-11-11T14:00:00
Esperion Therapeutics Inc Third Quarter Earnings Conference Call for 20252025-11-06T08:00:00
Esperion Therapeutics Inc Third Quarter Earnings Results for 20252025-11-06T00:00:00
H.C. Wainwright 27(th) Annual Global Investment Conference2025-09-08T14:00:00
Cantor Global Healthcare Conference2025-09-03T09:45:00
Esperion Therapeutics Inc Second Quarter Earnings Conference Call for 20252025-08-05T08:00:00
Esperion Therapeutics Inc Second Quarter Earnings Results for 20252025-08-05T00:00:00
Esperion Therapeutics Inc Annual General Meeting for 20252025-05-29T08:00:00
H.C. Wainwright's 3rd Annual BioConnect Investor Conference2025-05-20T10:00:00
The Citizens Life Sciences Conference2025-05-08T12:30:00
Esperion Therapeutics Inc First Quarter Earnings Conference Call for 20252025-05-06T08:00:00
Esperion Therapeutics Inc First Quarter Earnings Results for 20252025-05-06T00:00:00
Annual Needham Virtual Healthcare Conference2025-04-07T08:45:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.